The Pharmacokinetics of 12 Week Continuous Patch Use

Boston Medical Center30 enrolled

Overview

Investigators propose a descriptive pharmacokinetic study of the serum hormone levels of estrogen and progesterone with extended use (12 weeks) of the contraceptive patch. The primary objective is to assess the change in serum ethinyl estradiol (EE2) levels over 12 weeks of continuous contraceptive patch use. The secondary objective is assessing the the norelgestromin (NGMN) levels over the 12 weeks of continuous contraceptive patch use.

For women who are seeking alternatives to long-acting contraceptives, the oral contraceptive pill and the contraceptive ring are often prescribed in an extended manner (12 weeks straight). The contraceptive patch, however, is not routinely prescribed in this way. Concerns have been raised that hormone levels, in particular estrogen, are higher among patch users than those who use oral contraception or the vaginal ring and that this may contribute to an increased risk of clot. However, few studies have actually looked at these hormone levels in women with extended use of the contraceptive patch. The investigators plan to enroll eligible women age 18-39 who are willing to use the contraceptive patch continuously for twelve weeks, and can adhere to the study requirements for follow-up. All participants will have weekly serum assessments of ethinyl estradiol and norelgestromin levels. The investigators will enroll 30 women, in anticipation of a 33% attrition rate, with the goal of obtaining completed data on 20 participants. The study duration for an individual participant will be 12 weeks and the duration of the entire study will be one year.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Pharmacokinetics

Interventions

Xulane Contraceptive PatchDEVICE

Extended use (12 weeks) of contraceptive patch

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 39 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Willing and able to come to the clinic to have blood drawn weekly for 12 weeks, biweekly during weeks 4, 8, and 12, and for 3 days after the final patch is removed for blood draws for a total of 18 blood draws * Willing and able to abstain from using any other hormonal contraceptive method while in the study and for the week prior to starting the study Exclusion Criteria: * Body Mass Index greater than 35 * Personal or Family History of Venothromboembolism * Personal History of Migraines with Aura * Personal History of Migraines without Aura * Tobacco use greater than or equal to 15 cigarettes per day * Current Pregnancy * History of or Current Diagnosis of Cancer

Locations (1)

Boston Medical Center

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Change in Serum EE2 Levels Over 12 Weeks of Continuous Contraceptive Patch Use

Liquid chromatography-tandem triple quadrupole mass spectrometry was utilized to assess EE2

Time frame: Total of 18 blood draws - once at the end of each patch week and two times during weeks four, eight and twelve (with the additional blood draw occurring mid-week); and blood draws performed for three continuous days after the final patch was removed

Secondary Outcomes

NGMN Levels Over 12 Weeks of Continuous Patch Use

Liquid chromatography-tandem triple quadrupole mass spectrometry was utilized to assess NGMN

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.